AI Science Tracker
EN

Machine-learning prioritization informed preclinical study of luteolin in heart-failure models

The First College of Clinical Medicine, Guangxi University of Chinese Medicine, Nanning, China · 2 Oct 2026 · medicine

Discovery

Machine-learning prioritization informed preclinical study of luteolin in heart-failure models

Source check: Source checked. Not independent scientific confirmation.

Finding: Machine-learning analysis prioritized a candidate gene signature for investigation of luteolin in cell and rat heart-failure models. The study reports changes in cardiac injury measures alongside the signature. This is preclinical evidence without independent clinical validation and does not establish treatment efficacy in people.

Technology: Machine-learning combinations prioritized a gene signature from bioinformatic target sets for experimental follow-up.

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Machine-learning combinations prioritized a gene signature from bioinformatic target sets for experimental follow-up.
Test and result
Cell and rat models were used for experimental follow-up of the learned signature and proposed pathway; no independent clinical cohort was tested.
Limitation / still unknown
Preclinical models do not establish efficacy in people; authors note absent gene-editing validation.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2026.1977166/full

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary full-text review as recorded in case evidence; record-level claim and attribution review..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.